From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Is Stuart Ashman lying again?

By Tom Winnifrith | Thursday 15 February 2024

Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

My real beef with Stuart Ashman, the CEO of Skinbiotherapeutics (SBTX) is not his grotesque pay package and the fact that he snaffled a pay rise last year when his company headed backwards operationally. Nor is it that he tells overt porkies with his “Rules are rules” claims. My real gripe is, as explained in bearcast today, how poor decisions made by him have cost we loyal shareholders badly. Losing 2/3 of the share price in less than three months is worse than careless. But back to the lying.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



Anpario – a recovery Buy?...

Thursday »


Bearcast issue update: all should be well



Oracle Power: Cynical Foul

Time left: 22:20:15